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Current evidence suggests that regulation of extracellular matrix (ECM) accumulation by
ﬁbrogenic transforming growth factor (TGF)-β and platelet-derived growth factor (PDGF) sig-
nals involves different mechanisms in acute and chronic liver injuries, even though hepatic
stellate cells (HSC) are the principal effecter in both cases. As a result of chronic liver
damage, HSC undergo progressive activation to become myoﬁbroblasts (MFB)-like cells.
Our current review will discuss the differential regulation of TGF-β signaling between HSC
and MFB in vitro and in vivo. Smad proteins, which convey signals from TGF-β recep-
tors to the nucleus, have intermediate linker regions between conserved Mad-homology
(MH) 1 and MH2 domains. TGF-β type I receptor and Ras-associated kinases differentially
phosphorylate Smad2 and Smad3 to create COOH-terminally (C), linker (L), or dually (L/C)
phosphorylated (p) isoforms. After acute liver injury, TGF-β and PDGF synergistically pro-
mote collagen synthesis in the activated HSC via pSmad2L/C and pSmad3L/C pathways.
To avoid unlimited ECM deposition, Smad7 induced byTGF-β negatively regulates the ﬁbro-
genicTGF-β signaling. In contrast,TGF-β and PDGF can transmit the ﬁbrogenic pSmad2L/C
and mitogenic pSmad3L signals in MFB throughout chronic liver injury, because Smad7
cannot be induced by the pSmad3L pathway. This lack of Smad7 induction might lead to
constitutive ﬁbrogenesis in MFB, which eventually develop into accelerated liver ﬁbrosis.
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INTRODUCTION
Current evidence suggests that regulation of extracellular matrix
(ECM) accumulation in acute and chronic liver injuries involves
different mechanisms, even though hepatic stellate cells (HSC) are
the principal effecter in both cases (Friedman, 2010). HSC charac-
terized by retinoid droplets in the cytoplasm (Figure 1), are present
in the space of Disse in close contact with hepatocytes and sinu-
soidal endothelial cells.WhenHSCare activated, they lose retinoid,
and show increased proliferation, motility, and ECM production
(Brenner, 2009). As a result of chronic liver damage,HSC undergo
progressive activation to become myoﬁbroblasts (MFB)-like cells
(Inagaki and Okazaki, 2007).
Transforming growth factor (TGF)-β is a central regulator in
chronic liver disease contributing to ﬁbrogenesis through inﬂam-
mation (Dooley and Ten Dijke, 2012). On the other hand, platelet-
derived growth factor (PDGF) through tyrosine kinase receptor is
the most powerful mitogen for HSC, and also promotes liver ﬁbro-
sis (Pinzani, 1999).Within inﬂammatorymicroenvironment,both
TGF-β and PDGF are secreted by platelets and Kupffer cells (Pin-
zani and Macias-Barragan, 2010). A signiﬁcant increase in TGF-β
expression is observed in the activated HSC and MFB, thus indi-
cating that TGF-β acts as an autocrine positive regulator for ECM
Abbreviations: CDK, cyclin-dependent kinase; ECM, extracellular matrix; HSC,
hepatic stellate cells; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated
protein kinase; MFB, myoﬁbroblasts; PAI-1, plasminogen activator inhibitor-1;
PDGF, platelet-derived growth factor; pSmadC, C-terminal phosphorylated Smad;
pSmadL, linker-phosphorylated Smad; TGF-β, transforming growth factor-β.
production. Responsiveness of ECM production to TGF-β is tran-
sient in the process of tissue repair such as liver regeneration after
acute liver injury (Date et al., 1998, 2000), thus suggesting that
some regulatory mechanisms for the TGF-β signal are present in
the activated HSC. In contrast, persistent TGF-β signal associated
with the accelerated ECM accumulation is a common ﬁnding in
human chronic liver diseases of different etiologies (Kisseleva and
Brenner, 2008), indicating that MFB lose their negative regulation
for ECM accumulation.
Progress over the past 10 years has disclosed important details
of how the TGF-β family elicits its responses (Heldin et al., 1997;
Wrana, 2000; Shi and Massague, 2003; Guo and Wang, 2009).
Smads, central mediators conveying signals from receptors for
TGF-β superfamily members to the nucleus, are modular pro-
teins with conserved Mad-homology (MH)1, intermediate linker,
and MH2 domains (Shi and Massague, 2003). In cell-signaling
pathways, various transcription factors are phosphorylated atmul-
tiple sites by upstream kinases. Catalytically active TGF-β type
I receptor (TβRI) phosphorylates COOH-tail serine residues of
receptor-activated Smad (R-Smad), which include Smad2 and the
highly similar protein Smad3 (Wrana, 2000). Mitogenic signals
alternatively cause phosphorylation of R-Smad at speciﬁc sites in
their middle linker regions (Kretzschmar et al., 1999; Matsuura
et al., 2004; Mori et al., 2004; Kamaraju and Roberts, 2005; Seki-
moto et al., 2007; Matsuzaki et al., 2009). After phosphorylated
R-Smad rapidly oligomerize with Smad4, this complex translo-
cates to the nucleus, where it regulates transcription of target
genes. Antagonistic Smad7 acts in opposition to R-Smads and
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FIGURE 1 | Phenotypic alternation of HSC during acute and chronic
liver injuries. Quiescent hepatic stellate cells (HSC) are characterized by
retinoid droplets in the cytoplasm. Following single liver injury, HSC
transiently acquire an activated phenotype, which includes extracellular
matrix (ECM) synthesis, proliferation, and migration. HSC move from the
space of Disse to sites of damage where the activated HSC contribute to
tissue repair by producing large amounts of collagens. Prolonged exposure
to chronic injury, HSC undergo constitutive activation to become
myoﬁbroblasts (MFB)-like cells, which persistently induce deposition of
ECM and liver ﬁbrosis. Contraction of MFB contributes to increased portal
resistance during liver ﬁbrosis that presumably is reversible before the
thickened septae, intrahepatic shunts, and lobular distortion of cirrhosis
develop, leading to ﬁxed increases in portal pressure.
Smad4, forming stable associations with the activated type I recep-
tors, and preventing the phosphorylation of R-Smads (Hayashi
et al., 1997; Nakao et al., 1997). The transcription of the Smad7
gene is regulated by TGF-β signaling through direct binding of
Smad3 and Smad4 to the Smad7 promoter (Nagarajan et al.,
1999; von Gersdorff et al., 2000). Therefore, Smad7 functions in a
negative-feedback loop to terminate or reduce the strength of the
signal.
Monitoring phosphorylation status of signaling molecules is a
key step in dissecting their pathways. In Smad signaling, phospho-
rylation of not only COOH-tail but also linker regions of R-Smad
is likely to be important in regulating Smad activity under phys-
iologic and pathologic conditions (Liu, 2006). In this review, we
ﬁrst examine Smad signaling speciﬁcity derives from spatial and
temporal dynamics of domain-speciﬁc R-Smad phosphorylation
in response to TGF-β and/or PDGF. We next consider how TGF-
β signal together with PDGF promotes collagen synthesis in the
activated HSC after acute liver injury. Then, we examine constitu-
tive ﬁbrogenic TGF-β signal in MFB during chronic liver injury.
Finally, we consider differential regulation of ECM accumulation
between HSC and MFB.
CANONICAL TGF-β SIGNAL TRANSDUCTION
Transforming growth factor-β initiates signalingbybinding to type
I and type II receptor serine/threonine kinase on the cell surface.
R-Smads are phosphorylated by the activated TβRI on the C-
terminal SXS motif (Derynck and Miyazono, 2008). The activated
R-Smads form the complex with the common partner Smad4. The
complex translocates to the nucleus, where they regulate target
gene expression by interaction with other transcription factors,
co-activators, and co-repressors (Heldin et al., 1997; Wrana, 2000;
Shi and Massague, 2003; Guo and Wang, 2009). This pathway is
regulated by several autoinhibitory feedback loops. In particular,
Smad7 interacts stably with activated TβRI to inhibit COOH-tail
phosphorylation of R-Smads (Nakao et al., 1997).
PDGF SIGNAL TRANSDUCTION
Platelet-derived growth factor is not only a potent mitogen but
also a ﬁbrogenic growth factor known to synergize with TGF-β
(Pinzani and Macias-Barragan, 2010). Signaling by PDGF begins
by interaction with trans-membrane receptor tyrosine kinases
(Heldin andWestermark, 1999). Multiple signaling pathways orig-
inating from the receptors have been identiﬁed. The most promi-
nent pathways are mediated by members of the mitogen-activated
protein kinase (MAPK) family, which includes the extracellular
signal-regulated protein kinase (ERK) pathway and two stress-
activated protein kinase (SAPK) pathways: the c-Jun N-terminal
kinase (JNK) and the p38 pathway (Robinson and Cobb, 1997).
MAPK is capable of phosphorylating many transcription factors,
which are important in initiating cell proliferation and migration.
MULTIPLE LEVELS OF CROSSTALK EXIST BETWEEN TGF-β
AND JNK SIGNALING PATHWAYS
Transforming growth factor-β elicits signaling responses through
non-Smad pathways that are generally considered as important
effecter pathways for Ras/MAPK in response to PDGF (Derynck
and Zhang, 2003). Notably, JNK activates AP-1 consisting of
c-Jun that cooperates with nuclear Smads in mediating TGF-β-
induced transcriptional responses (Derynck and Zhang, 2003).
Thus, Smad-mediated signaling pathway is controlled by or func-
tions in conjunction with other non-Smad transcription factors
governed by JNK.
AlthoughCOOH-tail phosphorylation byTβRI is a key event in
R-Smad activation, additional phosphorylation can positively and
negatively regulate R-Smads pathway. Smad2 and Smad3 contain
two conservedpolypeptide segments, theMH1andMH2domains,
joined by a less conserved linker region (Shi and Massague, 2003).
The linker domain undergoes regulatory phosphorylation by JNK
and cyclin-dependent kinase (CDK) pathways (Matsuura et al.,
2004; Mori et al., 2004).
In one set of inﬂuential experiments, JNK phosphorylates
Smad3 outside its COOH-tail phosphorylation site, and enhances
activation and nuclear translocation of Smad3 (Engel et al., 1999).
Furthermore, activation of MAPK kinase 1 (MEKK-1), an acti-
vator of JNK and ERK MAPK, leads to phosphorylation and
activation of Smad2 (Brown et al., 1999). This mechanism may
explain the ability of ﬂuid shear stress or some growth factors to
activate Smad2 (de Caestecker et al., 1998; Matsuzaki et al., 2009).
We further identify phosphorylation sites for JNK in the linker
regions of Smad2 and Smad3 (Sekimoto et al., 2007). Thus, mul-
tiple levels of crosstalk exist between TGF-β and JNK signaling
pathways.
MULTIPLE Smad PHOSPHOISOFORMS EXIST
JNK simultaneously activates linker-phosphorylated Smad and
non-Smad signaling, with both usually operating in parallel.
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Biologic signiﬁcance of linker-phosphorylated Smad pathway is
therefore difﬁcult to assess in isolation. Antibodies (Abs) reactive
with structurally related phosphorylated peptides are emerging as
valuable tools for determining phosphorylation sites in vivo, and
for investigating their distinct signals via phosphorylated domains.
We therefore generated the domain-speciﬁc Abs, which selectively
distinguish between the phosphorylated linker regions and the C-
terminal regions of Smad2 and Smad3. Using the Abs, we have
investigated for linker-phosphorylated R-Smads pathway, with a
particular focus on how JNK modulates TβRI signaling through
Smad linker phosphorylation.
Domain-speciﬁc phospho-R-Smad Abs have allowed us to
reveal that TβRI and JNK/CDK4 differentially phosphorylate
R-Smads to create three phosphorylated forms (phosphoiso-
forms): COOH-terminally phosphorylated R-Smad (pSmad2C
and pSmad3C), linker-phosphorylated R-Smad (pSmad2L and
pSmad3L), and dually phosphorylated R-Smad (pSmad2L/C and
pSmad3L/C;Matsuzaki, 2006, 2012; Sapkota et al., 2006;Wrighton
et al., 2009). Except for pSmad2L with cytoplasmic localization
(Kretzschmar et al., 1999; Mori et al., 2004), the other phosphoiso-
forms are localized to cell nuclei (Furukawa et al., 2003; Mori et al.,
2004; Yamagata et al., 2005; Yoshida et al., 2005; Matsuzaki et al.,
2007; Sekimoto et al., 2007; Alarcon et al., 2009; Matsuzaki, 2009;
Murata et al., 2009; Nagata et al., 2009; Kawamata et al., 2011).
Linker phosphorylation can modify COOH-terminally phospho-
rylatedR-Smad signaling (Kretzschmar et al., 1999;Matsuura et al.,
2004; Mori et al., 2004; Ho et al., 2005; Sekimoto et al., 2007;
Matsuzaki, 2009).
Differential localization of kinases and phosphatases in the
cytoplasm or nucleus raises the intriguing possibility of different
temporal dynamics for cytoplasmic or nuclear R-Smad phospho-
isoforms, and adds to the repertoire of signaling responses that
determine cell-fate decisions (Matsuzaki, 2011). Immunohisto-
chemical and immunoﬂuorescence analyses using speciﬁc Abs
in human tissues can examine clinical signiﬁcance of context-
dependent and cell type-speciﬁc signaling mediated by R-Smad
phosphoisoforms, by comparison of tissue/cellular localization of
these phosphoisoforms in various pathologic specimens.
DIFFERENTIAL PHOSPHO-Smad SIGNALING BETWEEN HSC
AND MFB IN VITRO
Liu (2006) group previously reported that Smad3 is phosphory-
lated by CDK4 in vivo and in vitro. CDK4-mediated phospho-
rylation of Smad3 at its linker region inhibits its transcriptional
activity and the anti-proliferative activity of TGF-β in ﬁbroblasts
(Matsuura et al., 2004;Wang et al., 2009). Importantly,COOH-tail
phosphorylation of Smad3 is necessary for TGF-β-induced phos-
phorylation of Smad3 at its linker region in ﬁbroblasts (Wang
et al., 2009; Matsuura et al., 2010). Consistent with these observa-
tions concerning Smad3,we have conﬁrmed that the nuclear cyclin
D1/CDK4 complex of ﬁbroblasts activated by TGF-β and PDGF
signaling directly phosphorylates the linker segment of pSmad2C
to produce pSmad2L/C (Matsuzaki et al., 2009). The expression of
c-Myc in ﬁbroblasts is initially repressed by TGF-β, but subsequent
cyclin D1/CDK4 undergoes a complete functional change to stim-
ulate c-Myc (Matsuzaki et al., 2009). TGF-β inhibits cell growth
by down-regulating the c-Myc via the pSmad2C and pSmad3C
pathways (Figure 2A, left). However, signaling activated by TGF-β
and PDGF can enhance ﬁbroblast growth by up-regulating c-Myc
via the CDK4-dependent pSmad2L/C and pSmad3L/C pathways
in cell nuclei (Figure 2A, right). Moreover, Hayashida et al. (2003)
reported that pSmad3L/C increases collagen I synthesis in human
mesangial cells. We further reported that co-treatment of primary
cultured HSC with TGF-β and PDGF enhances transcription of
collagen I gene via pSmad3L/C pathway (Furukawa et al., 2003;
Yoshida et al., 2005). Importantly, TGF-β-mediated Smad7 in
HSC terminates the ﬁbrogenic signals via the pSmad2L/C and
pSmad3L/C pathways (Tahashi et al., 2002; Yoshida et al., 2005).
Primary cultured HSC are activated into MFB-like cells after
being cultured on plastic dishes. The morphologic features of the
cell line closely resembled a MFB-like morphology characterized
by spindle shape, cell enlargement, and reduction of the size of
intracellular vacuoles (Rockey et al., 1993). InMFB,PDGF induces
pSmad3L via the activated JNK pathway (Yoshida et al., 2005). The
JNK-mediated Smad3L phosphorylation leads to hetero-complex
of Smad3 with Smad4 in the nucleus (Mori et al., 2004; Seki-
moto et al., 2007). On the other hand, activated JNK retains most
Smad2 protein in the cytoplasm (Kretzschmar et al., 1999; Seki-
moto et al., 2007). Smad2 can accumulate in the nucleus only if
its C-terminus is phosphorylated under conditions of sustained
linker phosphorylation by JNK. After COOH-tail phosphoryla-
tion of cytoplasmic pSmad2L by TβRI, pSmad2L/C undergoes
translocation to the nucleus where it binds to the pSmad3L and
Smad4 complex (Furukawa et al., 2003; Matsuzaki et al., 2009;
Figure 2B, right), which then in turn stimulates plasminogen
activator inhibitor (PAI)-1 transcription (Furukawa et al., 2003).
The level of PAI-1 is signiﬁcantly elevated in ﬁbrotic liver, and
PAI-1 overexpression contributes to excessive accumulation of
collagen and other ECM proteins, while lack of PAI-1 protects
liver ﬁbrosis in response to injury-related proﬁbrotic TGF-β sig-
nals (Hu et al., 2009). In contrast to Smad7 induction in HSC via
pSmad3C pathway, pSmad3L cannot induce Smad7 transcript in
MFB (Tahashi et al., 2002;Tahashi et al.,unpublisheddata).Collec-
tively, ﬁbrogenic TGF-β signal can constitutively accelerate ECM
accumulation in MFB by upregulation of PAI-1 protein under a
low level of Smad7.
DIFFERENTIAL PHOSPHO-Smad SIGNALING BETWEEN THE
ACTIVATED HSC DURING ACUTE LIVER INJURY AND MFB
DURING CHRONIC LIVER INJURY
Signaling by TGF-β was indispensable for ECM synthesis dur-
ing remodeling of liver disease (Moriya et al., 2011). As TGF-β is
secreted in a biologically inactive form, the important step in reg-
ulating its biological activity is the conversion of the latent form
into the active one. The matricellular protein thrombospondin-
1 (TSP-1) was ﬁrst shown as a component of the α-granule in
platelets and can act as a major activator of latent TGF-β (Mosher,
1990; Crawford et al., 1998). Hayashi et al. (2011) recently identi-
ﬁed TSP-1 as an inhibitory element in regulating liver regeneration
via TGF-β1 activation. Their group also intensively investigates
new therapeutic strategies targeting local TGF-β activation in
ﬁbrogenesis.
To clarify the differential TGF-β signals between in acute
and chronic liver injuries, we previously analyzed the sequential
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FIGURE 2 | Differential regulation of fibrogenic phospho-Smad signaling
between HSC during acute liver injury and MFB during chronic liver
injury. (A) Phospho-Smad signaling involved in tissue repair. TGF-β inhibits
HSC growth by down-regulating c-Myc expression by pSmad2C and
pSmad3C pathways (left); TGF-β signaling in turn enhances HSC growth and
collagen synthesis via the CDK4-dependent pSmad2L/C and pSmad3L/C
pathways induced by PDGF signal (right). However, Smad7 induced by
pSmad3L/C signal terminates the ﬁbrogenic phospho-Smad signaling. This
negative-feedback mechanism of the ﬁbrogenic TGF-β/PDGF signal results in a
transient collagen synthesis in the activated HSC, which may thus contribute
to tissue repair. (B) Phospho-Smad signaling involved in ﬁbrogenesis. In MFB,
PDGF activates JNK, which phosphorylates Smad2L and Smad3L (left). The
JNK-mediated Smad3L phosphorylation leads to hetero-complex of Smad3
with Smad4 in the nucleus where the complex stimulates MFB growth by
upregulation of c-Myc transcription. After COOH-tail phosphorylation of
cytoplasmic pSmad2L byTGF-β signal, pSmad2L/C translocates to the
nucleus where it binds to the pSmad3L and Smad4 complex, which then
stimulates plasminogen activator inhibitor (PAI)-1 transcription (right). In
contrast of Smad7 induction in HSC via pSmad3C pathway, pSmad3L cannot
induce Smad7 in MFB (left). Under a low level of Smad7, the ﬁbrogenic
phospho-Smad signaling can constitutively promote ECM deposition by MFB,
which may eventually develop into accelerated liver ﬁbrosis.
expressions of TGF-β and its receptors in HSC and MFB dur-
ing acute and chronic CCl4 intoxication (Date et al., 1998, 2000).
The ﬁnding, however, merely shows an elevated TGF-β expres-
sion in both cases, and no differences in the expression of their
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receptors between HSC and MFB. This implies that a modiﬁca-
tion of postreceptor TGF-β signal in MFB is a more important
step for the process of liver ﬁbrosis during chronic liver injury.
To elucidate how cytostatic TGF-β signaling in HSC takes on
collagen-producing features within inﬂammatory microenviron-
ments during acute liver injury, we focus on the Smad pathway
investigating localization of pSmad2L/C andpSmad3L/C in chem-
ically injured rat livers. Nuclear localization of pSmad2L/C and
pSmad3L/C is seen in the activated HSC (Yoshida et al., 2005). In
particular, strong Smad2/3 phosphorylation at theCOOH-tail and
threonine residues in the linker regions is observed in the activated
HSC (Yoshida et al., 2005). pSmad2L/C and pSmad3L/C signaling
may mobilize HSC from the space of Disse to sites of damage,
where the activated HSC contribute to tissue repair by producing
large amounts of collagens. In HSC after acute liver injury, TβRI
activated by endogenous TGF-β signal phosphorylates Smad3C,
further up-regulating Smad7 transcription (Figure 2A, right).
Subsequently, Smad7 terminates the ﬁbrogenic TGF-β signal
mediated by pSmad2L/C and pSmad3L/C pathways. Smad7 could
be involved in tight restriction of R-Smads activation in HSC, and
regulates the intensity and duration of the TGF-β responses during
acute liver injury (Dooley et al., 2000; Tahashi et al., 2002).
The above regulatory mechanism, which avoids unlimited
accumulation of ECM proteins that promote liver ﬁbrosis, is
disrupted in MFB during chronic liver injury. During transdiffer-
entiation from HSC to MFB in culture, pSmad3C-mediated signal
decreases while the pSmad3L pathway predominates (Furukawa
et al., 2003; Figure 2B left). The observations fully support the
ﬁnding of pSmad3L rather than pSmad3C in nuclei of α-smooth
muscle actin (SMA)-immunoreactive MFB in portal tracts of
chronically HCV-infected liver specimens (Matsuzaki et al., 2007).
The presence of α-SMA is associated with transdifferentiation of
HSC into scar-forming MFB, an event that is considered pivotal in
the ﬁbrogenic response (Pinzani and Macias-Barragan, 2010). In
contrast to a transient increase in Smad7 in the activated HSC after
acute liver injury, Smad7 remains at a low level in MFB throughout
chronic liver injury (Tahashi et al., 2002). Because Smad7 cannot
be induced by the pSmad3L pathway (unpublished data), the lack
of Smad7 induction inMFBduring chronic liver diseasemight lead
to constitutive ﬁbrogenic TGF-β (Dooley et al., 2000; Stopa et al.,
2000; Tahashi et al., 2002). Accordingly, Smad7 overexpression
results in less accumulation of interstitial collagens and improves
liver ﬁbrosis (Dooley et al., 2003). Moreover, IFN-γ displays antiﬁ-
brotic effects by upregulation of Smad7 expression (Weng et al.,
2009).
CONCLUSION AND FUTURE PERSPECTIVES
Because TGF-β involves a variety of physiologic processes such
as liver regeneration, unraveling the molecular mechanisms of
the TGF-β signal in a pathologic condition is critical to our
understanding of its role in disease and the development of its
therapies (Bataller and Brenner, 2001). This review summarizes
Smad phosphoisoform-mediated signals in HSC, showing differ-
ences between in acute and chronic liver injuries. After acute liver
injury,TGF-β andPDGF synergistically enhance collagen synthesis
by activated HSC via the pSmad2L/C and pSmad3L/C pathways.
In recovery stage of acute liver injury, Smad7 induced by TGF-β
negatively regulates the ﬁbrogenic TGF-β signaling. In contrast,
PDGF-mediated pSmad3L cannot induce Smad7 in MFB even if
high concentration of TGF-β is observed in chronic liver diseases.
Under a low level of Smad7, MFB can constitutively exhibit the
mitogenic pSmad3L and ﬁbrogenic pSmad2L/C signaling, thereby
accelerating liver ﬁbrosis.
Transforming growth factor-β activates both Smad and non-
Smad signals, which crosstalk with JNK pathway at multiple levels
to provide context-dependent outcome (Derynck and Akhurst,
2007). Hence, context-speciﬁc effects in HSC can be gener-
ated by combined assemblies and spatiotemporal dynamics of
R-Smad phosphoisoforms and non-Smad pathway activation,
changes of interacting protein partners, and availability of repres-
sors/activators. Although our understanding of the molecular
mechanism of liver ﬁbrosis in MFB has signiﬁcantly advanced
during the past decade, much work is needed to deﬁne the
transcriptional regulatory networks in a context-speciﬁc way.
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